草的药理性质与阿尔茨海默氏症疾病的特殊参考
Himanshi Varshney1, Yasir Hasan Siddique1
1Department of Zoology, Section of Genetics, Faculty of Life Sciences, Drosophila Transgenic Laboratory, Aligarh Muslim University, Aligarh, 202002, Uttar Pradesh, India.
Current Alzheimer research
|May 26, 2023
概括
(Trigonella foenum-graecum) 通过减少氧化应激和改善认知功能,显示出对阿尔茨海默病的神经保护作用. 这篇评论强调了它对神经退行性疾病的治疗潜力.
科学领域:
- 药理学和草药医学 药理学和草药医学
- 神经科学和神经退行性疾病
背景情况:
- (Trigonella foenum-graecum) 是一种一年一度的植物,因其健康益处而被用于传统医学.
- 它的叶子和种子含有生物活性化合物,如类化合物,黄类化合物和素,有助于抗氧化,低血糖和低脂性质.
- 特定的化合物,如三素和迪奥斯基宁,显示出对抗阿尔茨海默病 (AD) 的神经保护的希望.
结论:
- 青显著缓解与神经退行性疾病,特别是阿尔茨海默病相关的病理症状.
- 证据表明,小松可以作为一种有价值的治疗剂来治疗这些疾病.
- 进一步研究小麦的机制和临床疗效是必要的.
相关概念视频
Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
Alzheimer's Disease: Overview
541
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
541
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
166
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
166
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators
474
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
474
Parkinson's Disease: Treatment
311
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
311


